Navigation Links
Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
Date:12/16/2008

cts for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone                            Robert Flamm, Ph.D.
    Russo Partners LLC                   Russo Partners LLC
    Tel: (619) 814-3510                  Tel: (212) 845-4226
    Fax: (619) 955-5318                  Email:
    Email:                               robert.flamm@russopartnersllc.com
    ian.stone@russopartnersllc.com       www.russopartnersllc.com

This News Release contains certain forward-looking statements and information regarding Helix's drug development plans, which statements and information can be identified by the use of forward-looking terminology such as "intends", "plans", "expects", "pending", "to occur", "objective", "believes", "on track", "is being designed", "proceeding", "intention", "to seek", "projects", "anticipates", "2009", "2010", "2012", "assuming", "continuing", "with a view to", "if", "developing", or variations thereon, or that events "could" or "would" occur or be achieved, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future, are not historical facts, and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: Helix's need for further financing, which may not be available; uncertainty whether the Company's products under development, includin
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
2. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
3. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
4. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
5. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
7. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
8. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
9. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
10. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
11. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013 Gilman Law LLP, a ... investigating Byetta lawsuits, is troubled by a new study ... and similar type 2 diabetes drugs are growing. ... Practices (ISMP), found that 71 Byetta pancreatic cancer reports ... Administration (FDA) as of June 30, 2012. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Headquartered in ... Levy Phillips & Konigsberg LLP (“LPK”) has ... White Plains, New York. LPK will better serve people ... Hudson Valley, including Westchester, Putnam, Rockland, Orange, and Dutchess ... affected by asbestos-related diseases throughout New York, New Jersey, ...
(Date:5/20/2013)... Online education provides the convenience, ... does not offer. According to the American Heart ... switching classroom learning to eLearning due to changing ... helped maximize training budgets, but it is also ... by 25–60%. A higher retention of content is ...
(Date:5/20/2013)... comprised over 24,000 Finnish subjects and was led ... a panel of 28 genetic markers improved detection ... disease (CHD) (10-year risk ≥20%) over traditional risk ... important preventive strategy for CHD, because the current ... "The results indicate that genetic markers could be ...
(Date:5/20/2013)... when a particular strain of avian influenza might become ... to be published in the International Journal Data ... University of Arizona, Tucson, and colleagues at the Huazhong ... Institute of Virology, explain that since 1997 several strains ... "bird flu" have infected people directly from their natural ...
Breaking Medicine News(10 mins):Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Predicting infectious influenza 2
... TV Ad Rebrands California Republican Party as the ,Yacht Party, for ... Supporting ,Yacht Tax, ... Courage Campaign have released a new ad branding the California,Republican Party ... that allows buyers of yachts and private jets to avoid paying,sales ...
... sellout for Actifirm(R), a,leading manufacturer of science-based skin ... on QVC Saturday, May 10., QVC program ... six Actifirm products, including 10% Z-Peel(R); Face Firm(TM);,Renovation ... discovery kit with Actifirm products for cleansing, exfoliating,and ...
... CMS Regulatory Action a,Serious Public Policy Misstep; Seniors, Nursing ... OH, IL, PA, NJ, MI, MA, WASHINGTON, May ... the Bush Administration,s $770 million cut to,Medicare-financed nursing home ... regulatory-driven cuts not only jeopardize seniors,access to quality nursing ...
... children exposed to tobacco smoke respond particularly well ... Jewish Medical and Research Center. Associate Professor ... also identified two biomarkers that may help physicians ... from montelukast. , These findings will help doctors ...
... - Significant Increase by 31,6% in Sales and 10,3 % in Net ... 31,6% of the Consolidated Sales to EUR 11,3m in the First ... - Increased by 12,7% of the Consolidated EBITDA to EUR 2,6m (from ... Net Profits (EAT) Increased by 10,3% to EUR 1,5m (from EUR 1,4m in ...
... Pepper Award nominations, DETROIT, May 13 ... lives of Michigan,s senior citizens have until June ... Shield of Michigan,s Claude,Pepper Award., The award ... volunteer efforts have made significant contributions to improving ...
Cached Medicine News:Health News:California Nurses Association, Courage Campaign, Arianna Huffington Team up for 'Yacht Party 2' TV Ad 2Health News:California Nurses Association, Courage Campaign, Arianna Huffington Team up for 'Yacht Party 2' TV Ad 3Health News:Actifirm Sells Out in First Hour Appearance on QVC 2Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 2Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 3Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 4Health News:Girls and children exposed to tobacco smoke benefit more from montelukast (singulair) 2Health News:KORRES Q1 2008 Results 2Health News:Blue Cross Blue Shield of Michigan Seeking Nominations for Outstanding Senior Advocates 2
(Date:5/20/2013)... 20, 2013  TRACE International today released its ... that prosecutions against individuals and government or business entities ... GER 2012 is the third in an ... trends. "Although the number of outbound enforcement ... remained a priority," said Alexandra Wrage ...
(Date:5/20/2013)... NEW YORK , May 20, 2013  Echo ... Rule 2.5 of the Irish Takeover Rules (the "Announcement"), ... Corporation, plc (NYSE: ELN ) to $12.50 ... financed, cash confirmed and not conditional on due diligence.  ... eliminated.  Royalty Pharma has reserved the right to waive ...
(Date:5/20/2013)... , May 20, 2013 A medical ... use both in space and on Earth was inducted ... The technology assures high quality, secure handling ... low-power ultrasound units, like those used in hospitals and ... the diagnostic imaging solution of choice for human space ...
Breaking Medicine Technology:TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3
... July 27, 2011 HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) ... six months ended June 30, 2011, after the close of ... A conference call with management is scheduled for 5:00 ... (being 7:00 am Australian Eastern Standard Time, Friday, August 5, ...
... July 27, 2011 Stryker Neurovascular, a division of ... and Platinum Science (MAPS) Trial during the Society of ... The MAPS Trial establishes a new standard for the ... (TAR)*, and proves that coiling is an excellent treatment ...
Cached Medicine Technology:HeartWare to Report Financial Results for Second Quarter of 2011 2Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms 2Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms 3
... TM-1 is a compact multi-functional ... precise measurement of UVA, UVB, ... all types of lens materials. ... connect with a personal computer ...
... This sleek, contoured instrument table ... room dcor, while providing a sturdy, ... wheelchair compatible design provides completely open ... make positioning quick and easy. The ...
If youre looking to expand your projection capabilities, without a major capital investment, consider Topcons CP-5D Chart Projector....
... corrected curve trial lenses are ground with the ... refractors and are invaluable in treating low vision ... manufacturers contain a disproportionately large number of lenses ... to produce, and fewer lenses in the higher ...
Medicine Products: